Temple Health is testing a tiny, flexible scaffold aimed at relieving a common problem for emphysema patients: overinflation ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled COPD of an eosinophilic phenotype who are already receiving triple therapy ...

AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...

Respiratory researchers are set to investigate a surprising driver of poor lung health: the body's metabolism.University of ...

Select your location to view local American Lung Association events and news near you.

UnityPoint is expanding its specialty care services by opening three new clinics, including plastic surgery, in the Waukee ...

Advances in lung cancer treatment have changed survival in ways that were unimaginable even a decade ago. Targeted drugs, ...

AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...

Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –– Recruitment ongoing for ...

Delaware-based AirNexis will develop, produce, and commercialize HSK39004, a dual inhibitor that can improve airflow ...

Mental health care is a confusing landscape. Consumers have questions including: Where and who do I go for what I’m ...